Literature DB >> 32188650

The role of complement in kidney disease.

Jamie Willows1, Matthew Brown2, Neil S Sheerin3.   

Abstract

While the complement cascade is an important component of the innate immune system, uncontrolled activation can cause severe disease. This concept is illustrated by the prototypical complement-mediated renal disease atypical haemolytic uraemic syndrome (aHUS), which causes renal failure if untreated but when managed with the complement inhibitor eculizumab leaves the patient vulnerable to infection with encapsulated organisms. Complement activation is also implicated in the pathogenesis of many other renal and non-renal diseases, necessitating an understanding of complement biology and diagnostics. We review renal diseases in which complement over-activation is known to cause tissue injury; aHUS and C3 glomerulopathy. We also discuss the contribution of complement more widely to the pathophysiology of renal disease, and highlight the significance and side effects of anti-complement therapy relevant to the general physician. © Royal College of Physicians 2020. All rights reserved.

Entities:  

Keywords:  C3 glomerulopathy; Complement; atypical haemolytic uraemic syndrome; glomerulonephritis n; thrombotic microangiopathy

Mesh:

Substances:

Year:  2020        PMID: 32188650      PMCID: PMC7081808          DOI: 10.7861/clinmed.2019-0452

Source DB:  PubMed          Journal:  Clin Med (Lond)        ISSN: 1470-2118            Impact factor:   2.659


  20 in total

Review 1.  Screening for complement system abnormalities in patients with atypical hemolytic uremic syndrome.

Authors:  David Kavanagh; Anna Richards; Veronique Fremeaux-Bacchi; Marina Noris; Timothy Goodship; Giuseppe Remuzzi; John P Atkinson
Journal:  Clin J Am Soc Nephrol       Date:  2007-02-14       Impact factor: 8.237

2.  C4d deposition in acute rejection: an independent long-term prognostic factor.

Authors:  Andrew M Herzenberg; John S Gill; Ognjenka Djurdjev; Alex B Magil
Journal:  J Am Soc Nephrol       Date:  2002-01       Impact factor: 10.121

Review 3.  Compendium of current complement therapeutics.

Authors:  Wioleta M Zelek; Long Xie; B Paul Morgan; Claire L Harris
Journal:  Mol Immunol       Date:  2019-08-22       Impact factor: 4.407

4.  Alternative complement pathway activation products in urine and kidneys of patients with ANCA-associated GN.

Authors:  Shen-Ju Gou; Jun Yuan; Chen Wang; Ming-Hui Zhao; Min Chen
Journal:  Clin J Am Soc Nephrol       Date:  2013-10-10       Impact factor: 8.237

5.  Complement activation in acute humoral renal allograft rejection: diagnostic significance of C4d deposits in peritubular capillaries.

Authors:  A B Collins; E E Schneeberger; M A Pascual; S L Saidman; W W Williams; N Tolkoff-Rubin; A B Cosimi; R B Colvin
Journal:  J Am Soc Nephrol       Date:  1999-10       Impact factor: 10.121

Review 6.  Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies.

Authors:  Julien Zuber; Fadi Fakhouri; Lubka T Roumenina; Chantal Loirat; Véronique Frémeaux-Bacchi
Journal:  Nat Rev Nephrol       Date:  2012-10-02       Impact factor: 28.314

7.  Predominant role for C5b-9 in renal ischemia/reperfusion injury.

Authors:  W Zhou; C A Farrar; K Abe; J R Pratt; J E Marsh; Y Wang; G L Stahl; S H Sacks
Journal:  J Clin Invest       Date:  2000-05       Impact factor: 14.808

Review 8.  Kidney Disease Caused by Dysregulation of the Complement Alternative Pathway: An Etiologic Approach.

Authors:  An S De Vriese; Sanjeev Sethi; Jens Van Praet; Karl A Nath; Fernando C Fervenza
Journal:  J Am Soc Nephrol       Date:  2015-07-16       Impact factor: 10.121

9.  Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference.

Authors:  Timothy H J Goodship; H Terence Cook; Fadi Fakhouri; Fernando C Fervenza; Véronique Frémeaux-Bacchi; David Kavanagh; Carla M Nester; Marina Noris; Matthew C Pickering; Santiago Rodríguez de Córdoba; Lubka T Roumenina; Sanjeev Sethi; Richard J H Smith
Journal:  Kidney Int       Date:  2016-12-16       Impact factor: 10.612

10.  High Risk for Invasive Meningococcal Disease Among Patients Receiving Eculizumab (Soliris) Despite Receipt of Meningococcal Vaccine.

Authors:  Lucy A McNamara; Nadav Topaz; Xin Wang; Susan Hariri; LeAnne Fox; Jessica R MacNeil
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2017-07-14       Impact factor: 17.586

View more
  7 in total

1.  The Increase in Circulating Levels of Pro-Inflammatory Chemokines, Cytokines, and Complement C5 in Canines with Impaired Kidney Function.

Authors:  Selena K Tavener; Dennis E Jewell; Kiran S Panickar
Journal:  Curr Issues Mol Biol       Date:  2022-04-11       Impact factor: 2.976

2.  Adipsin deficiency does not impact atherosclerosis development in Ldlr-/- mice.

Authors:  Longhua Liu; Michelle Chan; Lexiang Yu; Weidong Wang; Li Qiang
Journal:  Am J Physiol Endocrinol Metab       Date:  2020-11-02       Impact factor: 4.310

Review 3.  Immune Dysfunction in Uremia 2020.

Authors:  Gerald Cohen
Journal:  Toxins (Basel)       Date:  2020-07-05       Impact factor: 4.546

Review 4.  Treatment of Rare Inflammatory Kidney Diseases: Drugs Targeting the Terminal Complement Pathway.

Authors:  Marion Ort; Jasper Dingemanse; John van den Anker; Priska Kaufmann
Journal:  Front Immunol       Date:  2020-12-10       Impact factor: 7.561

5.  Serum Level of Complement C1q is Associated with Contrast-Associated Acute Kidney Injury in Patients Undergoing Emergency Percutaneous Coronary Intervention.

Authors:  Jun Tao; Chenglin Ye; Wen Dai; Di Li; Man Zhou; Yan Li
Journal:  J Inflamm Res       Date:  2021-12-24

6.  Renal transcriptome profiles in mice reveal the need for sufficient water intake irrespective of the drinking water type.

Authors:  Woo-Jeong Shon; Mi-Na Park; Jooyoung Lee; Ji-Hee Shin; Dong-Mi Shin
Journal:  Sci Rep       Date:  2022-06-28       Impact factor: 4.996

7.  Complement C7 is Specifically Expressed in Mesangial Cells and is a Potential Diagnostic Biomarker for Diabetic Nephropathy and is Regulated by miR-494-3p and miR-574-5p.

Authors:  Hang Guo; Zhiyue Yan; Yonghui Hu; Xitong Huang; Congqing Pan
Journal:  Diabetes Metab Syndr Obes       Date:  2021-07-05       Impact factor: 3.168

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.